Answers are grounded in this paper and cite their sources.
Review Article explores TL1A inhibitors targeting inflammation in IBD, suggesting new therapeutic approaches.
TL1A-DR3 integrates mucosal immunity with stromal injury, positioning inhibitors as a novel class to overcome IBD therapeutic ceilings by targeting the inflammation-fibrosis continuum.
No takes yet. Share an insight, caveat, or question.
Goyal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: